Targeting fibrosis: Mechanisms and clinical trials
M Zhao, L Wang, M Wang, S Zhou, Y Lu… - Signal transduction and …, 2022 - nature.com
Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …
dysregulated wound and connective tissue repair response. Multiple organs can develop …
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
Idiopathic pulmonary fibrosis: pathogenesis and management
G Sgalla, B Iovene, M Calvello, M Ori, F Varone… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …
[PDF][PDF] Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
In recent years, there has been an explosion of interest in how fibroblasts initiate, sustain,
and resolve inflammation across disease states. Fibroblasts contain heterogeneous subsets …
and resolve inflammation across disease states. Fibroblasts contain heterogeneous subsets …
Idiopathic pulmonary fibrosis (IPF): an overview
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …
progressive scarring of the lungs and the pathological hallmark of usual interstitial …
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
TM Maher, ME Strek - Respiratory research, 2019 - Springer
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …
The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
A Guenther, E Krauss, S Tello, J Wagner, B Paul… - Respiratory …, 2018 - Springer
Background Since 2009, IPF patients across Europe are recruited into the eurIPFreg,
providing epidemiological data and biomaterials for translational research. Methods The …
providing epidemiological data and biomaterials for translational research. Methods The …
Nintedanib: a review in fibrotic interstitial lung diseases
YN Lamb - Drugs, 2021 - Springer
Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological
processes, indicating the potential for common approaches to treatment. Nintedanib …
processes, indicating the potential for common approaches to treatment. Nintedanib …
Defining the activated fibroblast population in lung fibrosis using single-cell sequencing
R Peyser, S MacDonnell, Y Gao, L Cheng… - American journal of …, 2019 - atsjournals.org
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disorder driven by
unrelenting extracellular matrix deposition. Fibroblasts are recognized as the central …
unrelenting extracellular matrix deposition. Fibroblasts are recognized as the central …
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
BF Collins, G Raghu - European Respiratory Review, 2019 - Eur Respiratory Soc
Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …